Unicycive Therapeutics Implements 1-for-10 Reverse Stock Split

By Ahmed Jameison • Sunday, June 22 06:00 • Permanent Link

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) has announced a 1-for-10 reverse stock split of its common stock, effective from 4:01 p.m. Eastern Time on June 18, 2025. This move is aimed at increasing the bid price of the common stock to comply with the minimum bid price requirement for continued listing on the NASDAQ Capital Market. The implementation of the reverse stock split will result in a reduction of the issued and outstanding shares of the company's common stock from approximately 126,409,281 to approximately 12,640,929.

The reverse stock split will take effect on June 20, 2025, with the company's common stock expected to continue trading on the NASDAQ Capital Market under the symbol "UNCY." As a result of the reverse stock split, proportionate adjustments will be made to the per share exercise prices of outstanding stock options and warrants, as well as to the number of shares available for future awards granted under the company's stock incentive plans.

Unicycive Therapeutics is a clinical-stage biotechnology company focused on developing therapies for patients with kidney disease. The company's lead investigational treatment, oxylanthanum carbonate, is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Additionally, the company's second investigational treatment, Uni-494, is intended for the treatment of conditions related to acute kidney injury and has been granted orphan drug designation (ODD) by the FDA for the prevention of delayed graft function (DGF) in kidney transplant patients.

For more information about Unicycive Therapeutics, visit unicycive.com and follow the company on LinkedIn. Following these announcements, the company's shares moved -5.02%, and are now trading at a price of $6.34. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.